Marapharm Ventures Inc. (CNSX:MDM.CN) (OTCQX:MRPHF) (FSE:2M0) (“Marapharm” or the “Company”) is very pleased to announce, the Company has submitted the necessary amendments to its late-stage, Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”) application.
The Company is honored that Mr. Gabriel Cipes has accepted the appointment of Head of Quality Assurance and has approved the Company’s amendments to the Quality Assurance portion of its application.
Mr. Cipes is Vice President of Summerhill Pyramid Winery, one of the largest certified organic wineries in Canada. In 2010, he created the biodynamic and permaculture department at the winery which has been a major aspect of Summerhill’s ‘Organic’ branding and story, achieving the first certified Demeter vineyard in western Canada.
Mr. Cipes conducts Scientific Research & Experimental Development (SRED) developing polycultural management strategies to prove that one can not only produce diversified yields but also benefit the environment through incorporating biodiversity.
He has been developing and advising departments of environmental best practices such as waste water re-capture, ground water restoration strategies, recycling, composting and maintaining the zero waste principles and ethics.
Mr. Cipes serves on several organic and biodynamic certification boards such as, Demeter Canada, the Biodynamic Associations of BC (BDASBC) and the Certified Organic Associations of BC (COABC) where he provides oversight for all Certification Bodies (CB`s) in BC and oversees certification programs, Canadian Organic Regime (COR) and the BC Certified Organic Program (BCCOP).
“I feel honored to work with the mother herb and this Company. We are guided by holistic principles to ensure the highest quality and vibration of the medicine we will produce.” Gabriel Cipes
The Company has amended its location to a 40-acre site in Celista, BC, where (10) – 10,000 sq. ft, fully-funded, bio-secure engineered facilities will be constructed in two phases; maximizing our potential of a 100,000 sq. ft. ACMPR licence, once approved by Health Canada.
Ground preparation is now complete and building components have arrived on site.
“We share a common goal to advance this industry with sustainable, organic practices and science-driven research and development. We are grateful for the continued support of our shareholders who believe in this Company.” Linda Sampson, CEO
ABOUT MARAPHARM VENTURES INC.
Marapharm is a publicly traded company investing in the medical and recreational cannabis space, since 2014. Marapharm has rapidly expanded to include having cultivation, production and dispensary locations in the key North American states of Washington, Nevada, and California, and are seeking expansion opportunities worldwide.
In preparation for the federal government’s legalization of non-medical cannabis in October 2018, British Columbia has made a number of decisions about what our provincial regulatory framework will look like. https://www2.gov.bc.ca/gov/content/safety/public-safety/cannabis
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQX, and in Europe, ticker symbol 2M0 on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.
Neither the CSE, the FSE nor the OTCQX® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQX® accepts responsibility for the adequacy or accuracy of this release.
MARIJUANA INDUSTRY INVOLVEMENT:
Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate. Marapharm owns marijuana licenses in California and Nevada. Marijuana is legal in each state however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Marapharm’s ability to access private and public capital could be affected and or could not be available to support continuing operations. Marapharm’s business is conducted in a manner consistent with state law and is in compliance with licensing requirements. Copies of licenses are posted on Marapharm’s website. Marapharm has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with US federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the US.
FORWARD – LOOKING STATEMENTS: Certain statements in this release are forward-looking statements, which includes the Health Canada application, construction of facilities on property, the expected outcomes, and other matters. Forward looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding looking wording such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe” and “continue” or the negative thereof or similar variations. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, estimates, forecasts, projections and other forward-looking statements will not occur. Forward-looking statement are necessarily based upon a number of factors that, if untrue, could cause the actual results, performances or achievements of the Company to be materially different from future results, performances or achievements express or implied by such statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, present and future business strategies, the environment in which the Company will operate in the future, and other factors, many of which are beyond the control of the Company. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. Forward-looking statements are subject to a variety of risks and uncertainties, which could cause actual events, level of activity, performance or results to differ materially from those reflected in the forward-looking statements, including, without limitation: that laws and regulations may become more onerous; the ability of the Company to obtain necessary financing; the economy generally; the future growth, results of operations, performance and business prospectus and opportunities; changes in and the effect of government policies; demand for products; competition; anticipated and unanticipated costs; reliance on management; claims and legal proceedings; conflicts of interest; and market price and volatility of the Common Shares. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, the loss of key directors, employees, advisors or consultants, technology failures, failure to obtain a license from Health Canada, failure to develop new and innovative products, failure of counterparties to perform their contractual obligations and fees charged by service providers. Important factors that could cause actual results to differ materially from the Company’s expectations include, litigation, global economic climate, loss of key employees and consultants, additional funding requirements, changes in laws, competition, and failure of counterparties to perform their contractual obligations. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Investors are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above. The Canadian Securities Exchange has not reviewed, nor approved the contents of this news release.
View original content to download multimedia:http://www.prnewswire.com/news-releases/marapharm-ventures-inc-announces-health-canada-acmpr-application-update-300723393.html
SOURCE Marapharm Ventures Inc.